Table 3—

Change in overall Asthma Quality of Life Questionnaire (AQLQ) scores (from baseline to study endpoint) for patients in studies A, B and C, analysed by treatment group and level of control

Study AStudy BStudy C
Well controlledNot well controlledWell controlledNot well controlledWell controlledNot well controlled
Placebo0.24±0.47 (4)−0.40±0.93 (57)0.57±1.38 (8)−0.37±1.22 (72)
Salmeterol0.64±0.58 (13)−0.22±1.13 (69)1.19±0.89 (12)−0.35±1.14 (64)
FP0.99±1.08 (23)0.41±1.04 (54)0.68±0.66 (24)0.50±0.87 (53)
SFC1.11±0.82 (49)0.92±0.87 (35)1.14±1.08 (39)0.88±1.14 (38)0.99±0.69 (12)0.98±0.90 (35)
Budesonide0.02±0.52 (3)0.50±0.98 (42)
All patients0.97±0.87 (89)0.08±1.12 (215)0.96±1.00 (83)0.05±1.22 (227)0.80±0.76 (15)0.72±0.97 (77)
  • Data are presented as score change, mean±sd (n)

  • FP: fluticasone propionate

  • SFC: salmeterol/fluticasone propionate combination